CD274 and non-small cell lung carcinoma: NSCLC represents one of the first FDA-approved indications granted to pembrolizumab, as it received accelerated approval in October 2015 for patients with metastatic NSCLC with known tumoral PD-L1 expression that had progressed on or after platinum-based chemotherapy [64].